{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:30:51Z","timestamp":1782271851858,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["K08CA241319"],"award-info":[{"award-number":["K08CA241319"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["R01CA214018"],"award-info":[{"award-number":["R01CA214018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s11307-021-01666-1","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T15:02:41Z","timestamp":1635174161000},"page":"425-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma"],"prefix":"10.1007","volume":"24","author":[{"given":"Michael C.","family":"Bellavia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Nyiranshuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Latoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khanh-Van","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald J.","family":"Fecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhanchi","family":"Nigam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Gallazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Edinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-746X","authenticated-orcid":false,"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"issue":"16","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J et al (2019) Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 381(16):1535\u20131546","journal-title":"N Engl J Med"},{"issue":"11","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS et al (2016) Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 17(11):1558\u20131568","journal-title":"Lancet Oncol"},{"issue":"21","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017","journal-title":"N Engl J Med"},{"key":"1666_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA et al (2012) The role of BRAF V600 mutation in melanoma. J Transl Med 10:85\u201385","journal-title":"J Transl Med"},{"issue":"18","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","volume":"367","author":"KT Flaherty","year":"2012","unstructured":"Flaherty KT et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694\u20131703","journal-title":"N Engl J Med"},{"issue":"10","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R et al (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(10):1315\u20131327","journal-title":"Lancet Oncol"},{"issue":"5","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R et al (2018) Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 19(5):603\u2013615","journal-title":"Lancet Oncol"},{"issue":"8","key":"1666_CR8","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV et al (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871\u2013878","journal-title":"J Clin Oncol"},{"issue":"14","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345\u20131356","journal-title":"N Engl J Med"},{"issue":"8","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A et al (2015) Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16(8):908\u2013918","journal-title":"Lancet Oncol"},{"issue":"9","key":"1666_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C et al (2019) Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 20(9):1239\u20131251","journal-title":"Lancet Oncol"},{"key":"1666_CR12","first-page":"125","volume":"231","author":"B Holzmann","year":"1998","unstructured":"Holzmann B, Gosslar U, Bittner M (1998) Alpha 4 integrins and tumor metastasis. Curr Top Microbiol Immunol 231:125\u2013141","journal-title":"Curr Top Microbiol Immunol"},{"issue":"3","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1083\/jcb.119.3.653","volume":"119","author":"K Miyake","year":"1992","unstructured":"Miyake K et al (1992) Requirement for VLA-4 and VLA-5 integrins in lymphoma cells binding to and migration beneath stromal cells in culture. J Cell Biol 119(3):653\u2013662","journal-title":"J Cell Biol"},{"issue":"5","key":"1666_CR14","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/jnci\/87.5.366","volume":"87","author":"D Schadendorf","year":"1995","unstructured":"Schadendorf D et al (1995) Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels. J Natl Cancer Inst 87(5):366\u2013371","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1666_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10555-005-1572-1","volume":"24","author":"S Kuphal","year":"2005","unstructured":"Kuphal S, Bauer R, Bosserhoff A-K (2005) Integrin signaling in malignant melanoma. Cancer Metastasis Rev 24(2):195\u2013222","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"1666_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4049\/jimmunol.0803388","volume":"183","author":"Y-M Hyun","year":"2009","unstructured":"Hyun Y-M et al (2009) Activated integrin VLA-4 localizes to the lamellipodia and mediates T cell migration on VCAM-1. J Immunol 183(1):359\u2013369","journal-title":"J Immunol"},{"issue":"6364","key":"1666_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA et al (1992) Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356(6364):63\u201366","journal-title":"Nature"},{"issue":"24","key":"1666_CR18","doi-asserted-by":"publisher","first-page":"17215","DOI":"10.1074\/jbc.M113.536664","volume":"289","author":"G Halpert","year":"2014","unstructured":"Halpert G et al (2014) Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis. J Biol Chem 289(24):17215\u201317227","journal-title":"J Biol Chem"},{"issue":"7","key":"1666_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nchembio798","volume":"2","author":"L Peng","year":"2006","unstructured":"Peng L et al (2006) Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol 2(7):381\u2013389","journal-title":"Nat Chem Biol"},{"issue":"11","key":"1666_CR20","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.2967\/jnumed.114.144881","volume":"55","author":"W Beaino","year":"2014","unstructured":"Beaino W, Anderson CJ (2014) PET imaging of very late antigen-4 in melanoma: comparison of 68Ga- and 64Cu-labeled NODAGA and CB-TE1A1P-LLP2A conjugates. J Nucl Med 55(11):1856\u20131863","journal-title":"J Nucl Med"},{"issue":"6","key":"1666_CR21","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1021\/mp5006917","volume":"12","author":"W Beaino","year":"2015","unstructured":"Beaino W, Nedrow JR, Anderson CJ (2015) Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-targeted PET imaging and treatment of metastatic melanoma. Mol Pharm 12(6):1929\u20131938","journal-title":"Mol Pharm"},{"issue":"12","key":"1666_CR22","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2967\/jnumed.118.209510","volume":"59","author":"J Choi","year":"2018","unstructured":"Choi J et al (2018) Combined VLA-4\u2013targeted radionuclide therapy and immunotherapy in a mouse model of melanoma. J Nucl Med 59(12):1843\u20131849","journal-title":"J Nucl Med"},{"issue":"13","key":"1666_CR23","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1038\/sj.onc.1207405","volume":"23","author":"VO Melnikova","year":"2004","unstructured":"Melnikova VO et al (2004) Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23(13):2347\u20132356","journal-title":"Oncogene"},{"issue":"10","key":"1666_CR24","first-page":"2170","volume":"58","author":"BC Bastian","year":"1998","unstructured":"Bastian BC et al (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170\u20132175","journal-title":"Cancer Res"},{"issue":"7","key":"1666_CR25","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","volume":"2","author":"ZA Cooper","year":"2014","unstructured":"Cooper ZA et al (2014) Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunol Res 2(7):643\u2013654","journal-title":"Cancer Immunol Res"},{"key":"1666_CR26","doi-asserted-by":"crossref","unstructured":"Close DA, et al (2020) Unbiased high-throughput drug combination pilot screening identifies synergistic drug combinations effective against patient-derived and drug-resistant melanoma cell lines. SLAS Discov 2472555220970917","DOI":"10.1177\/2472555220970917"},{"issue":"2","key":"1666_CR27","doi-asserted-by":"publisher","first-page":"806","DOI":"10.4049\/jimmunol.1700231","volume":"199","author":"JT Mattila","year":"2017","unstructured":"Mattila JT et al (2017) Positron emission tomography imaging of macaques with tuberculosis identifies temporal changes in granuloma glucose metabolism and integrin \u03b14\u03b21\u2013expressing immune cells. J Immunol 199(2):806\u2013815","journal-title":"J Immunol"},{"issue":"1","key":"1666_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00401706.1969.10490657","volume":"11","author":"FE Grubbs","year":"1969","unstructured":"Grubbs FE (1969) Procedures for detecting outlying observations in samples. Technometrics 11(1):1\u201321","journal-title":"Technometrics"},{"issue":"2","key":"1666_CR29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jaad.2015.03.057","volume":"73","author":"HW Higgins","year":"2015","unstructured":"Higgins HW et al (2015) Melanoma in situ: Part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol 73(2):193\u2013203","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1666_CR30","doi-asserted-by":"publisher","first-page":"e87649","DOI":"10.1371\/journal.pone.0087649","volume":"9","author":"LD Hughes","year":"2014","unstructured":"Hughes LD, Rawle RJ, Boxer SG (2014) Choose your label wisely: water-soluble fluorophores often interact with lipid bilayers. PLOS ONE 9(2):e87649","journal-title":"PLOS ONE"},{"issue":"Suppl 1","key":"1666_CR31","first-page":"81","volume":"8","author":"OF Kuzu","year":"2015","unstructured":"Kuzu OF et al (2015) Current state of animal (mouse) modeling in melanoma research. Cancer Growth Metastasis 8(Suppl 1):81\u201394","journal-title":"Cancer Growth Metastasis"},{"issue":"5","key":"1666_CR32","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/ng.356","volume":"41","author":"D Dankort","year":"2009","unstructured":"Dankort D et al (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet 41(5):544\u2013552","journal-title":"Nat Genet"},{"issue":"5","key":"1666_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.coph.2012.07.016","volume":"12","author":"G Tomasi","year":"2012","unstructured":"Tomasi G, Rosso L (2012) PET imaging: implications for the future of therapy monitoring with PET\/CT in oncology. Curr Opin Pharmacol 12(5):569\u2013575","journal-title":"Curr Opin Pharmacol"},{"issue":"3","key":"1666_CR34","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1148\/radiol.2493080240","volume":"249","author":"B Krug","year":"2008","unstructured":"Krug B et al (2008) Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. Radiology 249(3):836\u2013844","journal-title":"Radiology"},{"issue":"2","key":"1666_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.soc.2007.03.004","volume":"16","author":"EA Choi","year":"2007","unstructured":"Choi EA, Gershenwald JE (2007) Imaging studies in patients with melanoma. Surg Oncol Clin N Am 16(2):403\u2013430","journal-title":"Surg Oncol Clin N Am"},{"issue":"3","key":"1666_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/00006231-199603000-00004","volume":"17","author":"G Larcos","year":"1996","unstructured":"Larcos G, Maisey MN (1996) FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 17(3):197\u2013198","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1666_CR37","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1148\/radiol.2442061099","volume":"244","author":"K Strobel","year":"2007","unstructured":"Strobel K et al (2007) High-risk melanoma: accuracy of FDG PET\/CT with added CT morphologic information for detection of metastases. Radiology 244(2):566\u2013574","journal-title":"Radiology"},{"issue":"1","key":"1666_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00259-017-3691-7","volume":"44","author":"ANM Wong","year":"2017","unstructured":"Wong ANM et al (2017) The advantages and challenges of using FDG PET\/CT for response assessment in melanoma in the era of targeted agents and immunotherapy. Eur J Nucl Med Mol Imaging 44(1):67\u201377","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"23","key":"1666_CR39","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.1073\/pnas.1922313117","volume":"117","author":"A Pyo","year":"2020","unstructured":"Pyo A et al (2020) Ultrasensitive detection of malignant melanoma using PET molecular imaging probes. Proc Natl Acad Sci 117(23):12991\u201312999","journal-title":"Proc Natl Acad Sci"},{"issue":"11","key":"1666_CR40","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1021\/acs.molpharmaceut.7b00607","volume":"14","author":"X Xu","year":"2017","unstructured":"Xu X et al (2017) Synthesis and preclinical evaluation of (18)F-PEG(3)-FPN for the detection of metastatic pigmented melanoma. Mol Pharm 14(11):3896\u20133905","journal-title":"Mol Pharm"},{"issue":"5","key":"1666_CR41","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2967\/jnumed.116.184564","volume":"58","author":"PK Garg","year":"2017","unstructured":"Garg PK et al (2017) 4-(11)C-Methoxy N-(2-diethylaminoethyl) benzamide: a novel probe to selectively target melanoma. J Nucl Med 58(5):827\u2013832","journal-title":"J Nucl Med"},{"issue":"11","key":"1666_CR42","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.112.104208","volume":"53","author":"AL V\u0101vere","year":"2012","unstructured":"V\u0101vere AL et al (2012) 64Cu-NH2-Bn-DOTA-hu14.18K322A, a PET radiotracer targeting neuroblastoma and melanoma. J Nucl Med 53(11):1772\u20131778","journal-title":"J Nucl Med"},{"issue":"44","key":"1666_CR43","doi-asserted-by":"publisher","first-page":"17489","DOI":"10.1073\/pnas.0708436104","volume":"104","author":"SD Voss","year":"2007","unstructured":"Voss SD et al (2007) Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A 104(44):17489\u201317493","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1666_CR44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.semnuclmed.2015.12.005","volume":"46","author":"A Norain","year":"2016","unstructured":"Norain A, Dadachova E (2016) Targeted radionuclide therapy of melanoma. Semin Nucl Med 46(3):250\u2013259","journal-title":"Semin Nucl Med"},{"issue":"2","key":"1666_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/jcp.21029","volume":"212","author":"M Klemke","year":"2007","unstructured":"Klemke M et al (2007) High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol 212(2):368\u2013374","journal-title":"J Cell Physiol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-021-01666-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T17:31:57Z","timestamp":1652117517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-021-01666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01666-1","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}